Tuesday, August 21, 2018 by Ralph Flores
Coagulation factor VIIa (brand name: NovoSeven, also known as factor VIIa) is a man-made protein used to prevent bleeding in patients with hemophilia. The drug is made to replicate naturally occurring factor VII (factor VIIa) in the body, where it is used to help the blood to clot.
In particular, the drug is administered to patients with hemophilia A and B who have developed antibodies against clotting proteins, such as factor VIII or factor IX, that help stop bleeding. Other conditions where factor VIIa is used include acquired hemophilia, congenital factor VII deficiency, or Glanzmann’s thrombasthenia (a rare genetic platelet disorder).
Factor VIIa comes in a powdered solution and is only administered in a clinical setting, where it is given by or under the direct supervision of a healthcare professional.
Common side effects after the administration of factor VIIa include:
If the following occurs, immediately seek emergency medical help:
If a person is taking medications to prevent bleeding episodes (e.g., factor IX complex or an anti-inhibitor coagulant complex), he should relay this information to his healthcare professional before starting with factor VIIa.
Factor VIIa use may affect the cardiovascular, hematologic, immunologic, respiratory, and nervous systems. In addition, it may also impact the blood, skin, liver, and gastrointestinal tract.
Currently, there is insufficient information on food items or diets that have a similar effect to factor VIIa. In traditional Chinese medicine, rhubarb is used to treat bleeding or hemorrhaging; however, studies are still needed if the plant can also be used to treat hemophilia. If you are to take rhubarb, discontinue after two weeks as it may cause gastrointestinal irritation.
Patients with hemophilia are usually given a daily exercise routine to strengthen the muscles and help prevent injuries that may aggravate the condition. In particular, stretches are preferred over contact sports, which can increase the risk of injury.
Coagulation factor VIIa is used to prevent bleeding in patients with hemophilia A and B who have developed antibodies against clotting proteins, such as factor VIII or factor IX, that help stop bleeding.
Coagulation factor VIIa is also given to patients with acquired hemophilia, congenital factor VII deficiency, or Glanzmann’s thrombasthenia.
Coagulation factor VIIa is only administered in a clinical setting.
Coagulation factor VIIa affects the cardiovascular, hematologic, immunologic, respiratory, and nervous systems.
Tagged Under: Tags: coagulation factor VIIa